Prevention of RSV disease in babies starts at HUS hospitals
RSV (respiratory syncytial virus) is the most common cause of respiratory infections leading to infant hospitalization. HUS offers an antibody developed against the RS virus called nirsevimab to infants and children who are at risk of severe RSV infection.
The aim of nirsevimab is to prevent the majority of severe illnesses and infant hospitalizations caused by RSV. Immunization with nirsevimab is voluntary and free of charge for families.
Nirsevimab is offered to all children born after August 1, 2024. HUS will offer nirsevimab to newborns in all its maternity hospitals from October 23, 2024. Children under the age of one year at risk for severe disease will be offered nirsevimab at HUS New Children's Hospital, Jorvi Hospital, and Hyvinkää Hospital from November 4, 2024, until the end of November.
The City of Helsinki and the wellbeing services counties of Uusimaa are responsible for administering nirsevimab according to their guidelines to healthy children born between August 1 – October 22, 2024
Nirsevimab is effective in preventing RSV infections
A long-acting antibody called nirsevimab is used to prevent RSV infections. It is administered as a single intramuscular injection. Nirsevimab is safe to administer even to newborns, and it provides efficient protection against RSV for the entire winter epidemic.
The product is very safe. It has been in use in several countries during the winter 2023–2024, where it prevented 80–90% of hospitalizations caused by RSV.
Keywords
Contacts
Director Jari Petäjä, p. 050 428 6630, jari.petaja@hus.fi
HUS Children and adolecents
Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
HUS-sammanslutningens styrelse behandlade HUS verksamhet och ekonomi7.10.2024 12:38:04 EEST | Pressmeddelande
HUS-sammanslutningens styrelse behandlade verksamheten och ekonomin för januari–augusti samt samarbetsavtalet för Södra Finlands samarbetsområde.
HUSin yhtymähallitus käsitteli HUSin toimintaa ja taloutta7.10.2024 12:38:04 EEST | Tiedote
HUSin yhtymähallitus käsitteli tammi−elokuun toimintaa ja taloutta sekä Etelä-Suomen yhteistyöalueen yhteistyösopimusta.
En kost som utesluter mjölk under den tidiga barndomen minskar inte användningen av mjölkprodukter i ungdomen och sänker inte D-vitaminnivån4.10.2024 08:53:35 EEST | Pressmeddelande
Komjölksallergi är den vanligaste allergin hos spädbarn i Finland. Enligt en nyligen färdigställd undersökning återspeglas inte en kost som utesluter mjölk under den tidiga barndomen i kosten i ungdomen, om komjölken införs i kosten enligt rekommendationerna när toleransen utvecklas. Hos de flesta unga som deltog i undersökningen låg också D-vitaminnivån på målnivån.
Varhaislapsuuden maidonvälttämisruokavalio ei vähennä nuoruusiässä maitotuotteiden käyttöä tai alenna D-vitamiinitasoa4.10.2024 08:53:35 EEST | Tiedote
Lehmänmaitoallergia on tavallisin allergia imeväisikäisillä Suomessa. Vasta valmistuneen tutkimuksen mukaan varhaislapsuuden lehmänmaidon välttämisruokavalio ei heijastu ruokavalioon nuoruusiässä, jos lehmänmaito otetaan suositusten mukaan ruokavalioon sietokyvyn kehittyessä. Suurimmalla osalla tutkimukseen osallistuneista nuorista myös D-vitamiinitaso oli tavoitetasolla.
HUS-sammanslutningens styrelse sammanträder den 7 oktober3.10.2024 15:15:38 EEST | Pressmeddelande
HUS-sammanslutningens styrelse sammanträder för att behandla bland annat verksamhet och ekonomi i januari–augusti.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom